Key facts
- It has raised $3.1M; the latest was Seed Round ($3.1M) in Mar 2025.
- Notable investors include Bpifrance, Emlyon Venture Labs, Le Tarmac.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for DrugOptimal
- ·The full record, as it builds
Funding rounds
No funding rounds for DrugOptimal are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DrugOptimal
Developer of a prescription automated software intended for detecting drug incompatibilities. The company's software leverages artificial intelligence to detect any physicochemical incompatibilities of digital prescriptions and, if necessary, declares them in the comments of the prescription validated by the doctor, enabling nurses to reduce complications and hospitalization time.
- Sector
- Healthcare
- HQ
- Meylan, France
- Founded
- 2022
- Website
- drugoptimal.com/
- Ownership
- Privately Held (backing)
DrugOptimal doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DrugOptimal shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DrugOptimal in its N-PORT filings yet. We sweep new filings monthly.